NCT03173690

Brief Summary

This study evaluates the effect of performing medicines reconciliation on patients admitted to an intensive care unit. Half of the patients will receive a medicines reconciliation at the intensive care unit. The other half will not. All included patients will receive medicines reconciliation after transfer to the ward.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 6, 2017

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 22, 2017

Completed
11 days until next milestone

First Posted

Study publicly available on registry

June 2, 2017

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 6, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2017

Completed
Last Updated

July 11, 2017

Status Verified

June 1, 2017

Enrollment Period

5 months

First QC Date

May 22, 2017

Last Update Submit

July 7, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of patients with at least one discrepancy between medications listed on hospital chart and medications used at home before hospital admittance

    Medications listed on the medication chart were recorded on a predefined form, this included information on dosage form, strength, dosage and administration time for each drug. The pharmacist performed medicines reconciliation either by interviewing the patient or by gathering information from other sources as the patient's general practitioner, next-to-kin or if relevant nursing home. Any deviations between the information from the medication chart and information obtained during medicines reconciliation was defined as a discrepancy.

    Medicines reconciliation is performed at randomisation and within 48 hours after transmission to the ward, assessed up to 28 days after randomisation

Secondary Outcomes (1)

  • Retrospective evaluation on the clinical relevance of the observed medical discrepancies

    Retrospectively, based on the information gathered from the day of randomisation up until 28 days after randomisation

Study Arms (2)

Intervention group

EXPERIMENTAL

Receive medication reconciliation at the ICU, pluss medication reconciliation at the ward

Other: Medication reconciliation at the ICUOther: Medication Reconciliation at the Ward

Control group

OTHER

No intervention at the ICU, medication reconciliation at the ward

Other: Medication Reconciliation at the Ward

Interventions

Medication reconciliation performed according to Integrated Medicines Management model

Intervention group

Medication reconciliation performed according to Integrated Medicines Management model

Control groupIntervention group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • belonging to the hospitals intake area
  • written informed concent by the patient or his/her next to kin

You may not qualify if:

  • Patients without next to kin
  • Not Norwegian speaking, in need of a translator
  • medication reconciliation performed earlier
  • Patients with Guillain-Barre or Myasthenia Gravis, due to long expectancy of stay
  • Short life expectancy, decided in cooperation with the physician

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Akershus university Hospital

Lørenskog, Akershus, Norway

RECRUITING

Study Officials

  • Silje E Oernes, PhD

    Hospital Pharmacy Enterprise, South Eastern Norway

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Masking Details
The care provider performing medicines reconciliation at ward is semimasked. The masking might be broken if the patients tells if he/she has been interviewed earlier in the study
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: The included patients are randomized to either intervention or control group. The intervention group receives medicines reconciliation at the intensive care unit. The control group receive standard pharmaceutical care, which now does not include medicines reconciliation. After the patients are transferred to care at the ward, medicines reconciliation is performed for all patients.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical pharmacist, Ph.d

Study Record Dates

First Submitted

May 22, 2017

First Posted

June 2, 2017

Study Start

February 6, 2017

Primary Completion

July 6, 2017

Study Completion

October 1, 2017

Last Updated

July 11, 2017

Record last verified: 2017-06

Data Sharing

IPD Sharing
Will not share

Locations